From 1 June 2016, Sylvant (siltuximab) 100 mg and 400 mg vials will be subsidised in the community and in District Health Board hospitals for the treatment of HHV-8 negative idiopathic multicentric Castleman’s disease. Special Authority criteria will apply.

The listing of Sylvant follows an announcement made by PHARMAC on 12 May 2016. Bedaquiline (Sirturo) is yet to be listed in the Schedule.

The Schedule also notes the listing of several new medicines on 1 July 2016.

For more details, go to: http://www.pharmac.govt.nz/2016/05/18/SU.pdf